Reports Q4 revenue $112.6M, consensus $110.26M. "We were pleased with the significant progress made throughout 2022 to advance our mission in the core symptomatic U.S. market while laying a strong foundation for future growth in our strategic pillars," said CEO Quentin Blackford. "We recognized more than 27% revenue growth for the full year, driven by strong volume contributions in addition to pricing tailwinds. We are also beginning to realize value from our increased focus on operational discipline, achieving positive adjusted EBITDA in the fourth quarter and more than 800-basis points of improvement in adjusted EBITDA margin for the full year 2022 compared to 2021. With another record of new Zio XT account openings in the fourth quarter, the issuance of the CMS Final Rule, and tangible progress made towards our pillars for long-term growth, I could not be more pleased with the ability of our entire organization to advance our mission to transform healthcare. Entering 2023, we believe that we are well positioned to continue driving significant value for patients, physicians, healthcare systems and our stakeholders. We are effectively navigating the operational headwinds highlighted in the latter part of 2022 and are guiding to another year of notable growth in 2023. We anticipate a number of significant and exciting catalysts throughout 2023, and I am truly excited by the opportunities we have to bring our innovative services to more patients across the world."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IRTC:
- iRhythm Technologies Announces Fourth Quarter andĀ Full Year 2022 Financial Results
- iRhythm Technologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
- iRhythm initiated with an Overweight at Wells Fargo
- iRhythm shares preliminary Q4 highlights, business update
- iRhythm Technologies Shares Preliminary Fourth Quarter 2022 Highlights and Business Update at the 41st Annual J.P. Morgan Healthcare Conference